Below you'll find answers to some commonly asked questions about ENHERTU.
HER2 is a protein that helps cells grow. When cells produce too much HER2, they may become cancerous. These cancer cells grow and divide faster than healthy cells, causing tumors to form. The cancer can also spread to other parts of the body.
In some cases, mutations in the HER2 gene can develop. These mutations often occur at the base of the HER2 protein inside the cell and can cause abnormal cell activity, promoting the growth of cancer cells.
You can ask your doctor about the HER2 status of your tumor to see if ENHERTU could be right for you.
ENHERTU is FDA approved for certain adults who have received a prior treatment and have the following types of tumors:
ENHERTU is made up of an antibody with the chemotherapy attached. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell. ENHERTU enters the cancer cells and the chemotherapy is released. The chemotherapy part of ENHERTU helps destroy the cancer cells as well as other cells nearby.
Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone. Talk to your doctor to see if it's right for you.
ENHERTU is given as an intravenous (IV) infusion. You will receive an ENHERTU infusion at your oncologist's office or at an infusion center.
For the treatment of early breast cancer:
- Before surgery, ENHERTU is given 1 time every three weeks (21-day treatment cycle) for 4 cycles followed by THP for 4 cycles
- After HER2-targeted treatment and surgery, ENHERTU is given 1 time every three weeks (21-day treatment cycle) for 14 cycles
For the treatment of metastatic breast cancer, HER2-mutant non-small cell lung cancer, gastric cancer, or other HER2-positive solid tumors:
- ENHERTU is given 1 time every three weeks (21-day treatment cycle)
- Your healthcare provider will decide how many treatments you need
Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.
The first ENHERTU infusion will take about 90 minutes so the healthcare provider can monitor any potential reactions. Future ENHERTU infusions should take about 30 minutes if your first infusion was well tolerated.
If you experience a reaction to the infusion, your healthcare provider may slow down or temporarily stop your infusion. If you have a severe infusion reaction, your healthcare provider may permanently stop your infusions.
Some of the most common side effects include nausea, fatigue, and hair loss. Others can be more serious as they may be related to lung problems, low white blood cell counts, heart problems, and harm to your unborn baby.
Additional possible side effects of ENHERTU can be found in the Important Safety Information below. If you experience side effects, talk to your doctor about ways to help manage them.
Learn what you can do before your next infusion
See how to manage some potential side effects
The ENHERTU4U program is designed to help you access and afford your prescribed ENHERTU treatment. The program includes benefits reviews, claims appeal information, paying for your prescription, and more.*
For more information about ENHERTU4U, please call 1-833-ENHERTU (1-833-364-3788) or visit ENHERTU4U.com.
*For eligible patients. Terms and conditions apply.
ENHERTU4U provides patients and their providers access and reimbursement support for ENHERTU. ENHERTU4U is administered and sponsored by Daiichi Sankyo, Inc. only. Reimbursement and access are not guaranteed.
If you don't have insurance, you may still qualify for the Patient Assistance Program. This program may provide eligible participants with ENHERTU for free. To determine if you are eligible, print out the PAP enrollment form and work with your doctor to complete it.
Explore how to save on ENHERTU
Finding support
Would you like to receive updates
about ENHERTU?